Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Kim Kelderman is Chief Executive Officer at Bio-Techne. OQRO lists 30 transactions filed with the SEC under this name, the latest on Nov 3, 2026, each linked to the official Form 4.
Chief Executive Officer
Disclosures on record
30
Companies involved
2
Bio-TechneTECH
27 disclosures · Jan 2025 – Nov 2026 · 2 sold
Nov 1, 20262,385disclosed Nov 3
DetailsOfficial recordAug 15, 202622Kdisclosed Nov 2
DetailsOfficial recordAug 15, 2026725disclosed Nov 2
DetailsOfficial recordAug 15, 2026683disclosed Nov 2
DetailsOfficial recordAug 15, 20268,543disclosed Nov 2
DetailsOfficial recordAug 15, 202612Kdisclosed Nov 2
DetailsOfficial recordAug 15, 202622Kdisclosed Nov 2
DetailsOfficial recordAug 15, 20268,698disclosed Nov 2
DetailsOfficial recordAug 15, 20268,190disclosed Nov 2
DetailsOfficial recordAug 15, 202624Kdisclosed Nov 2
DetailsOfficial recordAug 15, 202611Kdisclosed Nov 2
DetailsOfficial recordAug 17, 202694Kdisclosed Aug 19
DetailsOfficial recordAug 17, 202658Kdisclosed Aug 19
DetailsOfficial recordJul 28, 202635Kdisclosed Jul 30
DetailsOfficial recordJul 28, 202635Kdisclosed Jul 30
DetailsOfficial recordJul 28, 202629Kdisclosed Jul 30
DetailsOfficial recordMay 5, 202627Kdisclosed May 7
DetailsOfficial recordMay 5, 202627Kdisclosed May 7
DetailsOfficial recordMay 5, 202624Kdisclosed May 7
DetailsOfficial recordApr 22, 202611Kdisclosed Apr 24
DetailsOfficial recordApr 22, 202611Kdisclosed Apr 24
DetailsOfficial recordApr 22, 20261,363disclosed Apr 24
DetailsOfficial recordApr 14, 202637Kdisclosed Apr 16
DetailsOfficial recordApr 14, 202637Kdisclosed Apr 16
DetailsOfficial recordApr 14, 202632Kdisclosed Apr 16
DetailsOfficial recordJan 27, 2025Sold~$906Kdisclosed Jan 29
DetailsOfficial recordJan 27, 2025Sold~$129Kdisclosed Jan 29
DetailsOfficial recordCONMED CorporationCNMD
3 disclosures · Jun 2026 – Sep 2026
Sep 8, 2026500disclosed Sep 10
DetailsOfficial recordSep 8, 2026500disclosed Sep 10
DetailsOfficial recordJun 1, 20265,772disclosed Jun 3
DetailsOfficial recordKim Kelderman reported 0 open-market purchases and 8 sales here, 2021 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Kim Kelderman has no open-market purchase on record since 2021. Sales in 2 of the 6 years since 2021.
Kim Kelderman reported 0 open-market purchases and 8 sales since 2021; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $1.04M2×2 trades |
| 2021 | — | $1.72M6×6 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
As of the latest filing on , Kim Kelderman reported holding 80,509 shares of Bio-Techne (TECH), worth about $5.86M at the last close of $73 (Nov 18, 2026). Holdings are also on file at CONMED Corporation (CNMD); together they are worth about $5.88M.
Bio-Techne's proxy statement reports total compensation of $8.15M for Kim Kelderman for fiscal year 2025, after $2.64M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received. Proxy statement filed Sep 19, 2025
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Bio-Techne TECH | 80,509 | 81K direct | $73 | $5.86M | Nov 1, 2026 |
| CONMED Corporation CNMD | 500 | 500 direct | $48 | $24K | Sep 8, 2026 |
Is this Kim Kelderman’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
On the latest SEC Form 4, dated Nov 1, 2026, Kim Kelderman reported holding 80,509 shares of Bio-Techne (TECH). At the last close of $73 on Nov 18, 2026, that is about $5.86M. This is the stake disclosed in filings, not a net worth.
No public filing gives Kim Kelderman's net worth. What SEC Form 4 shows is the stock stake: 80,509 shares of Bio-Techne (TECH), about $5.86M at the last close, plus holdings in 1 other company, about $5.88M in all. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Bio-Techne's proxy statement reports total compensation of $8.15M for Kim Kelderman for fiscal year 2025, after $2.64M for 2024. The total is the one in the Summary Compensation Table: it counts stock awards at their value on the grant date, so it is not the cash received.
Kim Kelderman has no open-market purchase on record since 2021. Sales in 2 of the 6 years since 2021.
In SEC filings since 2021: no open-market purchase is on record; the latest open-market sale is from 2025.
Bio-Techne (TECH), from 2021 to 2025: 0 purchases and 8 sales.